ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- TCT 2024 Gets Underway With New Science Simultaneously Published Across JACC JournalsNew science presented at TCT 2024 and simultaneously published across the family of JACC Journals sheds light on topics including photon-counting detector-computed tomography (PCD-CT), new and emerging technologies for treating patients with cardiovascular diseases, fractional flow reserve (FFR) and resting full-cycle ratio for predicting myocardial ischemia, intravascular ultrasound (IVUS)-guided PCI in patients with diabetes and […]
- Tricuspid Valve Treatments Safe, Effective and Improve Quality of LifeTwo devices approved by the U.S. Food and Drug Administration (FDA) this year for tricuspid regurgitation (TR) are safe, effective and improve quality of life (QOL) at one year, according to studies published in JACC and simultaneously being presented at TCT 2024.
- T-TEER for Severe TR: Full TRILUMINATE Pivotal Cohort OutcomesWhat is the clinical impact of tricuspid regurgitation (TR) reduction with tricuspid transcatheter edge-to-edge repair (T-TEER)?
- One-Month Ticagrelor Monotherapy After PCI in Acute Coronary SyndromesThe goal of the IVUS-ACS/ULTIMATE-DAPT trial was to compare the efficacy of IVUS-guided vs. angiography-guided PCI among patients undergoing ACS PCI. Further, it sought to assess the safety and efficacy of ticagrelor monotherapy compared with dual antiplatelet therapy (DAPT) with aspirin and ticagrelor for 12 months following completion of 1-month DAPT for ACS PCI.
- Outcomes of Discontinuing Drug Treatment in HFrEF: Key PointsThe following are key points to remember from a state-of-the-art review on the consequences of discontinuing long-term drug treatment in patients with heart failure and reduced ejection fraction (HFrEF).